Journal of Gastrointestinal Cancer最新文献

{"title":"Correction: Treatment Outcomes and Prognostic Factors in Patients With Pancreatic Adenosquamous Carcinoma: A Single-Center Retrospective Study.","authors":"Kana Hosokawa, Kenji Ikezawa, Ryoji Takada, Masaki Kawabata, Hiroki Kishimoto, Yusuke Seiki, Ko Watsuji, Kazuhiro Kozumi, Makiko Urabe, Yugo Kai, Kaori Mukai, Tasuku Nakabori, Hiroyuki Uehara, Kazuyoshi Ohkawa","doi":"10.1007/s12029-026-01548-1","DOIUrl":"https://doi.org/10.1007/s12029-026-01548-1","url":null,"abstract":"","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"57 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148758901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Tumor-Associated Sarcopenia on Swallowing Function in Patients with Cancer: a Systematic Review and Meta-Analysis.","authors":"Qiumei Li, Jinlie Lin, Liping Lin, Yigen Hong, Shaofeng Zhao","doi":"10.1007/s12029-026-01528-5","DOIUrl":"10.1007/s12029-026-01528-5","url":null,"abstract":"<p><strong>Purpose: </strong>To explore whether the association between tumor-associated sarcopenia and dysphagia generalizes across tumor types and differs between head and neck cancer (HNC) and other cancers.</p><p><strong>Methods: </strong>Eligible studies published before December 31, 2024 were retrieved from PubMed, EMBASE, Web of Science, Cochrane Library, CNKI and Wanfang Data. Heterogeneity was evaluated by the I² statistic, with subgroup and meta-regression exploring heterogeneity sources. Leave-one-out sensitivity analysis, Harbord's test and trim-and-fill analysis assessed result robustness and publication bias.</p><p><strong>Results: </strong>Twelve studies (n = 2,889) were included. Sarcopenia was significantly associated with dysphagia (OR = 2.82, 95% CI 1.94 to 4.29, P < 0.001) with moderate heterogeneity (I² = 52.4%, P = 0.0172). Effect sizes were similar between HNC and other tumors (P = 0.9479). Sarcopenia assessment methods (P = 0.022) and dysphagia assessment tools (P = 0.018) independently explained heterogeneity. Sensitivity analysis confirmed stable results; trim-and-fill analysis showed reliable findings despite minor publication bias (P = 0.55).</p><p><strong>Conclusions: </strong>Sarcopenia is a universal independent associated factor for dysphagia across cancers, with no difference between HNC and other cancers. Routine screening and targeted interventions may reduce dysphagia risk and improve patient quality of life.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"57 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148759213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver Transplantation Following Hepatocellular Carcinoma Rupture and Long-Term Immunotherapy: A Case Report.","authors":"Lorenza Di Marco, Marco Scoppettuolo, Alessandra Pivetti, Nicola De Maria, Veronica Bernabucci, Antonio Colecchia, Cristian Caporali, Federico Casari, Annarita Pecchi, Andrea Spallanzani, Massimiliano Salati, Barbara Catellani, Gian Piero Guerrini, Stefano Di Sandro, Massimo Dominici, Fabrizio Di Benedetto","doi":"10.1007/s12029-026-01573-0","DOIUrl":"10.1007/s12029-026-01573-0","url":null,"abstract":"<p><strong>Aim: </strong>To report a case of advanced hepatocellular carcinoma (HCC) complicated by tumor rupture, successfully downstaged with combined oncolytic immunotherapy (Pexa-Vec) and a PD-1 inhibitor (Nivolumab), ultimately enabling liver transplantation (LT). This report highlights the potential role of immune checkpoint inhibitors (ICIs) as bridging therapy in otherwise ineligible patients.</p><p><strong>Methods: </strong>A 54-year-old male with HCV-related cirrhosis presented with multifocal, unresectable HCC (BCLC C) complicated by hemoperitoneum. Surgery was not indicated. He was enrolled in a Phase I/IIa trial of intralesional Pexa-Vec and intravenous Nivolumab (240 mg every 14 days). Percutaneous biopsies confirmed Edmondson-Steiner grade 2 HCC. Clinical, laboratory, and imaging follow-up were performed throughout therapy. Pre-transplant screening was performed after 4 years of stable disease.</p><p><strong>Results: </strong>The patient received three intralesional Pexa-Vec injections and 93 cycles of Nivolumab over four years, with only mild, transient adverse events. Imaging showed stable disease without extrahepatic spread. Pre-LT evaluation confirmed preserved liver function (Child-Pugh A5, ECOG 0). Immunotherapy was suspended 12 weeks before LT, and LT was performed successfully in September 2023. Post-transplant follow-up (24 months) revealed no recurrence of HCC or graft rejection. HCV was eradicated with direct-acting antivirals. Explant pathology showed complete necrosis in injected nodules and regressive changes in other lesions.</p><p><strong>Conclusions: </strong>ICIs alone or in combination with oncolytic immunotherapy may serve as novel downstaging strategies in advanced, ruptured HCC. Successful LT with long-term disease-free survival challenges traditional concerns about peritoneal seeding. Larger studies are required to define optimal patient selection, timing, and safety of pre-transplant ICIs. A 54-year-old man with advanced, ruptured liver cancer had an unexpectedly stable course over four years while receiving immunotherapy and an oncolytic virus. He later underwent a liver transplant and remains cancer-free two years later, illustrating the unpredictable nature of some severe liver cancer cases.</p><p><strong>Clinical trial registration: </strong>Not applicable.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"57 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13477448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148764155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relative Dose Intensity and Clinical Outcomes of Using Trifluridine/Tipiracil with or without Bevacizumab in Patients Aged ≥ 75 Years with Advanced or Recurrent Colorectal Cancer: a Single-Center Retrospective Study.","authors":"Aiko Tomiuchi, Michio Kimura, Yoshiaki Ikeda, Eiseki Usami","doi":"10.1007/s12029-026-01566-z","DOIUrl":"10.1007/s12029-026-01566-z","url":null,"abstract":"<p><strong>Purpose: </strong>Evidence regarding treatment intensity, tolerability, and outcomes of using trifluridine/tipiracil (FTD/TPI) with or without bevacizumab (BV) in older patients with metastatic colorectal cancer (mCRC) is limited. We compared relative dose intensity (RDI), toxicity, and survival between FTD/TPI monotherapy and FTD/TPI plus BV, and examined the relationship between RDI and overall survival (OS) in older patients.</p><p><strong>Methods: </strong>In this single-center retrospective study, patients aged ≥ 75 years with unresectable or recurrent mCRC who received FTD/TPI monotherapy or FTD/TPI plus BV were included. The primary endpoint was RDI; secondary endpoints included treatment exposure, adverse events, achieving RDI ≥ 80%, and OS. Landmark analysis at two treatment cycles and multivariable Cox regression were used to assess the independent effect of the RDI on OS.</p><p><strong>Results: </strong>Forty-nine patients were included. Median FTD/TPI RDI was 72.9% in the monotherapy group and 74.8% in the combination therapy group, with no significant difference in the proportion achieving an RDI ≥ 80%. Grade ≥ 3 neutropenia occurred in 60.5% of patients in the monotherapy group and 81.8% of patients in the combination therapy group. Hypertension and proteinuria were more frequent in the combination therapy group. Median OS was longer in the combination therapy group (18.3 vs. 8.3 months). RDI ≥ 80% was not associated with OS in landmark or Cox regression analyses. Age and baseline hemoglobin levels were independent prognostic factors.</p><p><strong>Conclusions: </strong>FTD/TPI monotherapy and FTD/TPI + BV had similar RDI but different toxicity profiles. RDI ≥ 80% did not independently predict OS. In older patients with mCRC, treatment selection, tolerability, and patient-specific factors may be more important than strict dose intensity. These findings suggest that individualized treatment strategies may be important, although further prospective studies are warranted.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"57 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148760442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nationwide Practice Patterns of Early Postoperative Kampo Medicine after Gastrectomy for Gastric Cancer: A Japanese Administrative Database Study.","authors":"Tsunehiko Maruyama, Kazuto Ikezawa, Hideo Suzuki, Tomohiro Kurokawa, Yoshimasa Akashi, Tatsuya Oda","doi":"10.1007/s12029-026-01570-3","DOIUrl":"10.1007/s12029-026-01570-3","url":null,"abstract":"<p><strong>Purpose: </strong>Kampo medicines are incorporated into early postoperative supportive care in Japan, but nationwide real-world data after gastrectomy are limited. We characterized early postoperative use of Daikenchuto and Rikkunshito and explored postoperative length of stay (LOS) as a secondary descriptive outcome.</p><p><strong>Methods: </strong>Using a Japanese Diagnosis Procedure Combination administrative database from 472 hospitals (August 2017-July 2022), we identified adults undergoing gastrectomy for gastric cancer. Early postoperative use was defined as administration within 7 postoperative days. Prescription rates were compared by hospital characteristics and surgical procedure (open vs. laparoscopic distal, total, and proximal gastrectomy). Postoperative LOS was calculated from surgery to discharge.</p><p><strong>Results: </strong>Among 26,097 eligible patients, 1,797 (6.9%) received Daikenchuto and 2,309 (8.8%) received Rikkunshito. Daikenchuto was more frequently used after open than laparoscopic surgery (8.3% vs. 5.7%) and was most often prescribed after open distal (8.9%) and open total gastrectomy (7.6%). Rikkunshito was more frequently prescribed in designated cancer hospitals and large hospitals (≥500 beds), and after distal or proximal gastrectomy than total gastrectomy (9.6% vs 6.3%). The median postoperative LOS was 12 days among Daikenchuto users versus 11 days among non-users, and 10 days among Rikkunshito users versus 11 days among non-users.</p><p><strong>Conclusion: </strong>Early postoperative Kampo prescribing after gastrectomy differed across institutions and surgical procedures. The principal finding of this study was nationwide variation in prescribing patterns. Postoperative LOS differed descriptively between users and non-users, although these comparisons were unadjusted and subject to substantial time-dependent and clinical confounding.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"57 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148759474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond PERISCOPE II: Redesigning Peritoneal-Directed Treatment for Gastric Cancer.","authors":"Eoghan Burke","doi":"10.1007/s12029-026-01568-x","DOIUrl":"10.1007/s12029-026-01568-x","url":null,"abstract":"<p><p>Peritoneal metastases remain a major therapeutic challenge in gastric cancer. PERISCOPE II provided the first direct randomised comparison of an integrated operative strategy with continued systemic therapy in patients selected for limited peritoneal disease. Gastrectomy, cytoreductive surgery (CRS) and sequential heated oxaliplatin-normothermic docetaxel did not improve survival and caused substantial morbidity. The trial result should thus exclude routine adoption of that pathway, but it should not be interpreted as proof that every form of peritoneal-directed treatment is futile. Its multicomponent intervention was undertaken after brief systemic treatment, without mandatory laparoscopic confirmation of peritoneal response before randomisation, and frequently disrupted further systemic therapy. Meanwhile, DRAGON-01 has shown that repeated normothermic intraperitoneal paclitaxel can improve survival when added to systemic treatment, and STOPGAP has demonstrated the feasibility of serial laparoscopic reassessment and response-directed surgery in a Western pathway. Future trials should therefore separate two questions: whether intraperitoneal therapy adds benefit to contemporary biomarker-directed systemic treatment, and whether operative consolidation benefits the exceptional responders thereby identified. Surgery should become the consequence of demonstrated systemic and peritoneal response, not the intervention used to discover it.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"57 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148759406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiomics for Prediction of Microsatellite Instability Status in Gastric Cancer: A Systematic Review and Meta-Analysis.","authors":"Qitao Gou, Kangmeng Wang, Xin He, Xiang Zhang","doi":"10.1007/s12029-026-01569-w","DOIUrl":"10.1007/s12029-026-01569-w","url":null,"abstract":"<p><strong>Background: </strong>Microsatellite instability (MSI) is a key biomarker for immunotherapy in gastric cancer (GC), but preoperative non-invasive prediction remains challenging. Radiomics is promising; however, a systematic evaluation of its diagnostic performance with explicit consideration of overfitting and model comparison is lacking.</p><p><strong>Methods: </strong>We systematically searched PubMed, Embase, Web of Science, and Cochrane Library up to March 25, 2026, for studies on radiomics for preoperative MSI prediction in GC. A bivariate random-effects model pooled sensitivity, specificity, and diagnostic odds ratio (DOR). Subgroup analyses were performed by model type, data source, validation type, and algorithm.</p><p><strong>Results: </strong>Thirteen studies (2,447 patients) were included. In validation sets (17 data points), the pooled AUC was 0.82 (95% CI: 0.79-0.85), sensitivity 0.79 (95% CI: 0.73-0.84), and specificity 0.72 (95% CI: 0.67-0.76). Performance was higher in training sets (AUC 0.88). Combined models (radiomics plus clinical features) achieved higher specificity than radiomics models (0.75 vs. 0.68) in validation sets. Externally and internally validated models had comparable AUC (0.82 vs. 0.83). Machine learning did not outperform logistic regression.</p><p><strong>Conclusion: </strong>radiomics demonstrates moderate diagnostic accuracy for preoperative MSI prediction in GC. Combined models improve specificity, aiding patient selection. Differences between training and validation performance underscore the need for rigorous external validation. Prospective, multicenter studies are warranted.</p><p><strong>Registration: </strong>This research was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was prospectively registered with the PROSPERO database under registration number CRD420251148467. The protocol is available at: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251148467 .</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"57 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148760683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Efficacy of Fibrin Sealants and Polyglycolic Acid Sheets in Reducing Postoperative Hemorrhage Following Gastric Endoscopic Submucosal Dissection: A Meta-analysis of Randomized and Observational Studies\".","authors":"Nawazish Ali, Mohammad Osama, Aqib Ali, Ahmed Mustafa Khawaja, Waqar Ahmad, Fatma Ikram","doi":"10.1007/s12029-026-01571-2","DOIUrl":"10.1007/s12029-026-01571-2","url":null,"abstract":"","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"57 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148764907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing of Immune Checkpoint Inhibitor Initiation and Overall Survival in Advanced Gastric Cancer: A Multicenter Real-World Study Using Clone-Censor-Weight Analysis.","authors":"Shota Shimizu, Tomoyuki Matsunaga, Sadamu Takahashi, Hirohiko Kuroda, Hiroaki Saito, Tomohiro Osaki, Kenji Fukuda, Akemi Iwamoto, Kenjiro Taniguchi, Yoji Fukumoto, Yuji Shishido, Kozo Miyatani, Teruhisa Sakamoto, Yoshiyuki Fujiwara","doi":"10.1007/s12029-026-01567-y","DOIUrl":"10.1007/s12029-026-01567-y","url":null,"abstract":"<p><strong>Purpose: </strong>The optimal timing of immune checkpoint inhibitor (ICI) initiation in advanced gastric cancer (GC) remains unclear. In this study, we evaluated the association between ICI initiation timing, tumor response, and survival outcomes in a real-world setting for GC.</p><p><strong>Methods: </strong>We conducted a multicenter retrospective study of patients with unresectable or recurrent GC who initiated first-line chemotherapy between January 2015 and September 2025. To adjust for immortal time bias, a clone-censor-weight (CCW) approach was applied to evaluate overall survival (OS) among the patients who received ICIs. Tumor response was assessed in patients treated with first-line S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (CapeOX), with logistic regression analysis performed to identify factors associated with response.</p><p><strong>Results: </strong>A total of 359 GC patients were included, of whom 219 received ICIs and were included in the CCW analysis. The ICI initiation timing was not significantly associated with OS (hazard ratio 1.03, 95% confidence interval (CI) 0.71-1.51, P = 0.88). In contrast, the addition of ICIs significantly improved the objective response rate compared with chemotherapy alone (56.3% vs. 34.2%, P = 0.017). ICI use remained independently associated with an improved response (odds ratio 2.31, 95% CI 1.07-5.01, P = 0.034).</p><p><strong>Conclusions: </strong>In this real-world GC patient cohort, ICI initiation timing was not associated with survival, despite an improved tumor response with an ICI-containing therapeutic regimen. These findings suggest a potential discordance between short-term response and long-term survival outcomes in advanced GC.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"57 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148764918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of Liver Function and Tumor Burden Scores in Patients with HCC After Transarterial Radioembolization - Retrospective Single Center Analysis.","authors":"Aaron Schindler, Anne Beeskow, Janett Fischer, Sebastian Ebel, Timm Denecke, Daniel Seehofer, Thomas Lincke, Osama Sabri, Thomas Berg, Florian van Bömmel","doi":"10.1007/s12029-026-01572-1","DOIUrl":"10.1007/s12029-026-01572-1","url":null,"abstract":"<p><strong>Background: </strong>Transarterial radioembolization (TARE) is an established locoregional therapy for advanced hepatocellular carcinoma (HCC). Prognosis depends on both tumor progression and hepatic function. Despite multiple scoring systems, predicting therapeutic benefit remains challenging.</p><p><strong>Materials and methods: </strong>This study evaluated the prognostic performance of established scores (BCLC, HAP, CLIP, OKUDA, ALBI, MELD, and Child-Pugh) for survival after TARE in 86 patients with HCC and liver cirrhosis. Predictive accuracy for 3-, 6-, and 12-month survival was assessed using ROC curve analyses.</p><p><strong>Results: </strong>The median age was 67 years, and the predominant etiologies were alcohol-related and metabolic dysfunction-associated steatotic liver disease. Only ALBI and OKUDA were significantly associated with overall survival (HR 3.10; p < 0.001 and HR 5.02; p = 0.018, respectively). ALBI and CLIP showed the highest predictive accuracy for 3-, 6-, and 12-month survival. In multivariablee analysis, ALBI and OKUDA remained independent predictors of 12-month survival (HR 3.70; p = 0.001 and HR 5.01; p = 0.025, respectively). The ALBI score worsened significantly within 12 weeks after TARE (p < 0.001).</p><p><strong>Conclusion: </strong>The ALBI score was the strongest predictor of survival following TARE. In contrast, tumor burden showed limited prognostic relevance, underscoring hepatic functional reserve as a key determinant of outcomes after locoregional liver cancer therapy.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"57 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13473070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148723193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}